The present invention relates to a composition for preventing, improving or treating a mental disorder, the composition containing a Lactobacillus sp. bacteria-derived vesicle as an active ingredient. The present inventors have confirmed that, when a Lactobacillus sp. bacteria-derived vesicle is administered to a stress and depression animal model, resistance to stress efficiently increases, and an effect of treating chronically persisting long-term depression behavior is exhibited, and thus the Lactobacillus sp. bacteria-derived vesicle, according to the present invention, is expected to be capable of being usefully employed in developing a medicine or a functional health food, etc., for preventing, reducing the symptoms of or treating a mental disorder such as stress, anxiety disorder, post-traumatic stress disorder, panic disorder, depression, autism spectrum disorder, attention deficit hyperactivity disorder and schizophrenia.

Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

The present invention provides a maleate, phosphate, sulfate, hydrochloride of a cyclohexane derivative, N′-[trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea, as shown in Formula I and crystal forms thereof. The crystal forms have low hygroscopicity and good stability and are convenient for long-term storage and transportation; or the crystal forms have a long half-life in vivo, high bioavailability and small individual difference, and thus have obvious clinical application advantages.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be infected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.